Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome

ÖZTÜRK B., Gurbuz A. S., Durak Z. E., ÖZTÜRK H. S.

GYNECOLOGICAL ENDOCRINOLOGY, cilt.35, sa.2, ss.138-141, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 2
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1080/09513590.2018.1505847
  • Dergi Adı: GYNECOLOGICAL ENDOCRINOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.138-141
  • Anahtar Kelimeler: Adenosine deaminase, dipeptidyl peptidase-4, Polycystic ovary syndrome, GLUCAGON-LIKE PEPTIDE-1, ANTIMULLERIAN HORMONE, INCRETIN ACTION, WOMEN, INSULIN, ADIPOCYTES, PREGNANCY, METFORMIN, ROSIGLITAZONE, PATHOGENESIS
  • Ankara Üniversitesi Adresli: Evet

Özet

Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in reproductive age women and insulin resistance (IR) and hyperinsulinism play a critical role in the pathogenesis. Glucagon-like peptide-1 (GLP-1), promotes insulin secretion, inhibits glucagon secretion. GLP-1 is degraded by dipeptidyl peptidase-4 (DPP-4). DPP-4, also interacts with adenosine deaminase (ADA). Therefore, IR may have a significant connection with ADA activity. The aim of this study is to compare levels of DPP-4 and ADA enzymes in PCOS and infertile patients. Forty-four patients with PCOS and 44 infertile patients with normal ovarian reserve were enrolled in the study. Serum ADA, DPP-4, AMH, glucose and insulin levels were measured. HOMA-IR method was used to assess insulin sensitivity. ADA, DPP-4, AMH, HOMA-IR (p < .05) and insulin levels (p < .01) were found to be increased in PCOS patients. Considering all study participants AMH levels were found to be positively correlated with ADA (r: 0.734) and DPP-4 (r: 0.449) levels. Also ADA levels were found to be positively correlated with DPP-4 (r: 0.472), insulin (r: 0.216) and HOMA-IR (r: 0.223). Our findings about the elevation of DPP-4 levels in patients with PCOS suggest that the use of DPP-4 inhibitors may be beneficial in treatment of these patients.